AI can help design AI systems: automating architecture choices, discovering algorithms, and optimizing hardware ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter. Life and ...

Although the Bulgarian State Television Female Vocal Choir formed less than a century ago, with a verifiable context and history, writers and listeners still treat the ensemble’s music with the same ...

Bowen Yang is leaving “Saturday Night Live” after this weekend’s Christmas show, in the middle of Season 51. “He has been there for seven years — time to move on,” said a person familiar with Yang’s ...

Nvidia's restraint — focusing on enabling the ecosystem rather than owning it — has helped cement its role as the ...

This article, presented in the backdrop of the debates on the state of political theory in India, argues that the terms of debate need to shift to include the question of method of doing political ...

A secretive scientist, Dr “Hap” Percy, studies people with near-death histories to test if consciousness can cross dimensions ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...